AI Insight
A new drug called daraxonrasib has shown significant effectiveness against pancreatic cancer by targeting KRAS mutations, which drive most pancreatic tumors and were previously considered "undruggable." In a major clinical trial involving patients with advanced pancreatic cancer, the treatment nearly doubled patient survival times and reduced the risk of death by 60% compared to standard treatment options.
Why it matters
This breakthrough offers hope for pancreatic cancer patients, who have historically faced extremely poor prognosis with limited treatment options. If approved, daraxonrasib could become a significant new therapeutic option for the majority of pancreatic cancer cases that harbor KRAS mutations.
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn’t be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
Source: Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival